Nothing has changed in the company except that every day it gets closer to FDA approval for Firdapse.
Catalyst is the only hope for a Firdapse approval by the FDA and even has the recent FDA designation as a "BREAKTHROUGH TREATMENT".
What a gift that just fell out of the sky to be able to buy CPRX shares at $2..25 when big buyers were just paying over $3.50.
CPRX will be in the teens next year that is right around the corner. Just look at ACAD and AEGR.
Management is clearly on top of everything and is leading a brilliant effort to gain FDA approval.
Smart money will use this opportunity to buy more.
Sentiment: Strong Buy